HomeNewsBusinessBudget 2023 | IRFC's market borrowing in 2023-24 to be nil

Budget 2023 | IRFC's market borrowing in 2023-24 to be nil

IRFC’s financials are strong and it has enough money to continue operations in 2023-24, the railway minister said.

February 03, 2023 / 17:50 IST
Story continues below Advertisement
The Railways ministry's Internal and Extra Budgetary Resources have fallen to Rs 52,783 crore in 2023-24 from Rs 95,943 crore in 2022-23. (Representative image)
The Railways ministry's Internal and Extra Budgetary Resources have fallen to Rs 52,783 crore in 2023-24 from Rs 95,943 crore in 2022-23. (Representative image)

Indian Railway Finance Corporation (IRFC), the market borrowing arm of Indian Railways, will not borrow any money in the form of debt in financial year 2023-24, according to Budget documents.

The government has listed IRFC's Internal and Extra-Budgetary Resources (IEBR) as negligible in 2023-24, indicating it will not look to borrow money to fund its capital expenditure.

Story continues below Advertisement

In 2022-23, IRFC's IEBR was set at Rs 66,500 crore as part of the Budgetary allocations. As part of the government's revised estimates, IRFC's IEBR for 2022-23 will come in at Rs 48,500 crore in 2022-23. In 2021-22 IRFC had borrowed Rs 60,683.41 crore from the market.

IEBR comprises funds by way of profits, loans and equity.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show